SCHEMBL6894250

SCHEMBL6894250

Nc1cc(C2CCC(C(=O)O)NC2)nc2c(-c3ccc(Cl)cc3)cnn12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 15/20 0.55
CCNA2 P20248 13/20 0.55
CDK2 P24941 13/20 0.55
CCNA1 P78396 13/20 0.55
NPC1 O15118 4/20 0.49
ALDH1A1 P00352 4/20 0.49
RAB9A P51151 4/20 0.49
KDM4E B2RXH2 3/20 0.49
MAPT P10636 3/20 0.49
MEN1 O00255 2/20 0.49
HPGD P15428 2/20 0.49
KMT2A Q03164 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.42
MAPK1 P28482 2/20 0.39
HCRTR1 O43613 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6893629 0.91 CHEK1 (0.63) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL10236515 0.91 CHEK1 (0.51) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL7883968 0.89 CHEK1 (0.52) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL6894338 0.88 CHEK1 (0.52) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL6894206 0.87 CHEK1 (0.56) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL6893627 0.87 CHEK1 (0.55) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL6893207 0.86 CHEK1 (0.52) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL7886619 0.85 CHEK1 (0.49) CHEK1CCNA2CDK2CCNA1
SCHEMBL7874910 0.85 CHEK1 (0.66) CHEK1CCNA2CDK2CCNA1
SCHEMBL10239412 0.85 CHEK1 (0.50) CHEK1CCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 CHEK1 2755/4885CCNA2 2265/4885CDK2 457/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.